Ribociclib

Healio spoke with Debu Tripathy, MD, about the use of targeted therapies in breast cancer.

Combinations of cyclin-dependent kinase 4/6 inhibitors and aromatase inhibitors appeared effective among older and younger women with hormone receptor-positive, HER2-negative metastatic breast cancer compared with aromatase inhibitors alone, according to results of an FDA pooled analysis published in Journal of Clinical Oncology.

During the past decade, several key preclinical studies established the biologic rationale for targeting cyclin-dependent kinase 4/6 in women with hormone receptor-positive breast cancer.